

Simon Beddows

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5688191/publications.pdf>

Version: 2024-02-01

69
papers

3,166
citations

159573

30
h-index

155644

55
g-index

70
all docs

70
docs citations

70
times ranked

3810
citing authors

#	ARTICLE	IF	CITATIONS
1	Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 565-580.	9.1	556
2	Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). <i>Lancet</i> , The, 2013, 382, 1795-1806.	13.7	306
3	Epidemiology of <i>Mycoplasma genitalium</i> in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). <i>International Journal of Epidemiology</i> , 2015, 44, 1982-1994.	1.9	117
4	Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2005, 79, 8812-8827.	3.4	115
5	Serotyping HIV Type 1 by Antibody Binding to the V3 Loop: Relationship to Viral Genotype. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1379-1386.	1.1	110
6	A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls. <i>PLoS ONE</i> , 2013, 8, e61825.	2.5	103
7	Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 28-33.	2.1	99
8	A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. <i>Virology</i> , 2007, 360, 329-340.	2.4	94
9	Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. <i>Emerging Infectious Diseases</i> , 2016, 22, 1732-1740.	4.3	77
10	The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. <i>Virology</i> , 2005, 338, 154-172.	2.4	76
11	Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site. <i>Journal of Virology</i> , 2003, 77, 1084-1091.	3.4	69
12	The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010–2016. <i>Journal of Infectious Diseases</i> , 2018, 218, 911-921.	4.0	67
13	Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. <i>Sexually Transmitted Infections</i> , 2012, 88, 212-217.	1.9	65
14	Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. <i>Vaccine</i> , 2018, 36, 4792-4799.	3.8	60
15	Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. <i>BMJ</i> , The, 2012, 344, e4168-e4168.	6.0	57
16	Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. <i>Vaccine</i> , 2011, 29, 8585-8590.	3.8	56
17	Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. <i>BMJ Open</i> , 2016, 6, e009915.	1.9	54
18	Geographic Diversity of Human Immunodeficiency Virus Type 1: Serologic Reactivity to env Epitopes and Relationship to Neutralization. <i>Journal of Infectious Diseases</i> , 1992, 165, 256-261.	4.0	51

#	ARTICLE	IF	CITATIONS
19	Comparison of the Antibody Repertoire Generated in Healthy Volunteers following Immunization with a Monomeric Recombinant gp120 Construct Derived from a CCR5/CXCR4-Using Human Immunodeficiency Virus Type 1 Isolate with Sera from Naturally Infected Individuals. <i>Journal of Virology</i> , 1999, 73, 1740-1745.	3.4	51
20	Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. <i>Vaccine</i> , 2012, 30, 3867-3875.	3.8	49
21	DNA methylation analysis in liquid-based cytology for cervical cancer screening. <i>International Journal of Cancer</i> , 2009, 125, 2995-3002.	5.1	47
22	Oral Human Papillomavirus Infection in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0157976.	2.5	47
23	Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. <i>Journal of Medical Virology</i> , 2003, 70, 337-342.	5.0	42
24	Human Papillomavirus 16, 18, 31 and 45 viral load, integration and methylation status stratified by cervical disease stage. <i>BMC Cancer</i> , 2014, 14, 384.	2.6	42
25	Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance: Table A1. <i>Sexually Transmitted Infections</i> , 2015, 91, 284-286.	1.9	42
26	Adaptation to Blockade of Human Immunodeficiency Virus Type 1 Entry Imposed by the Anti-CCR5 Monoclonal Antibody 2D7. <i>Virology</i> , 2001, 287, 382-390.	2.4	41
27	Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. <i>Journal of Medical Virology</i> , 2011, 83, 1744-1751.	5.0	40
28	Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1191-1198.	3.0	38
29	Systemic and Mucosal Immune Responses to Sublingual or Intramuscular Human Papilloma Virus Antigens in Healthy Female Volunteers. <i>PLoS ONE</i> , 2012, 7, e33736.	2.5	36
30	The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies. <i>Scientific Reports</i> , 2016, 6, 39730.	3.3	32
31	<i>Trichomonas vaginalis</i> infection is uncommon in the British general population: implications for clinical testing and public health screening. <i>Sexually Transmitted Infections</i> , 2018, 94, 226-229.	1.9	32
32	Long-Term Survivors in Nairobi: Complete HIV-1 RNA Sequences and Immunogenetic Associations. <i>Journal of Infectious Diseases</i> , 2004, 190, 697-701.	4.0	28
33	Construction and Characterization of Soluble, Cleaved, and Stabilized Trimeric Env Proteins Based on HIV Type 1 Env Subtype A. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 569-579.	1.1	26
34	High-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 842-853.	2.5	26
35	Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine. <i>Vaccine</i> , 2019, 37, 2455-2462.	3.8	26
36	Purified, Proteolytically Mature HIV Type 1 SOSIP gp140 Envelope Trimers. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 817-828.	1.1	25

#	ARTICLE	IF	CITATIONS
37	Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. <i>Vaccine</i> , 2014, 32, 1139-1146.	3.8	24
38	Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. <i>Virology</i> , 2006, 351, 121-132.	2.4	22
39	Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. <i>Vaccine</i> , 2017, 35, 3922-3929.	3.8	21
40	Amino acid sequence diversity of the major human papillomavirus capsid protein: Implications for current and next generation vaccines. <i>Infection, Genetics and Evolution</i> , 2013, 18, 151-159.	2.3	19
41	Male Circumcision and STI Acquisition in Britain: Evidence from a National Probability Sample Survey. <i>PLoS ONE</i> , 2015, 10, e0130396.	2.5	19
42	Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology. <i>Vaccine Journal</i> , 2012, 19, 449-451.	3.1	17
43	Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins. <i>Vaccine</i> , 2014, 32, 6548-6555.	3.8	17
44	Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine. <i>PLoS ONE</i> , 2015, 10, e0140926.	2.5	17
45	Confirmatory assays are essential when using molecular testing for <i>Neisseria gonorrhoeae</i> in low-prevalence settings: insights from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3): Table A1. <i>Sexually Transmitted Infections</i> , 2015, 91, 338-341.	1.9	17
46	Antimicrobial resistance in <i>Mycoplasma genitalium</i> sampled from the British general population. <i>Sexually Transmitted Infections</i> , 2020, 96, 464-468.	1.9	17
47	Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 36-41.	4.5	16
48	Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies. <i>Journal of Infectious Diseases</i> , 2019, 220, 1940-1945.	4.0	15
49	Epidemiology of genital warts in the British population: implications for HPV vaccination programmes. <i>Sexually Transmitted Infections</i> , 2019, 95, 386-390.	1.9	15
50	Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines. <i>Journal of Virology</i> , 2016, 90, 3247-3252.	3.4	13
51	Testing for sexually transmitted infections in a population-based sexual health survey: development of an acceptable ethical approach: Table 1. <i>Journal of Medical Ethics</i> , 2012, 38, 380-382.	1.8	12
52	Human papillomavirus type 16 long control region and E6 variants stratified by cervical disease stage. <i>Infection, Genetics and Evolution</i> , 2014, 26, 8-13.	2.3	12
53	Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype. <i>Journal of Virology</i> , 2015, 89, 7748-7757.	3.4	12
54	Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies. <i>Journal of General Virology</i> , 2017, 98, 1755-1761.	2.9	12

#	ARTICLE	IF	CITATIONS
55	Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies. <i>Journal of General Virology</i> , 2019, 100, 237-245.	2.9	10
56	Simple detection of point mutations associated with HIV-1 drug resistance. <i>Journal of Virological Methods</i> , 2001, 93, 145-156.	2.1	9
57	Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance. <i>MSphere</i> , 2018, 3, .	2.9	8
58	Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies. <i>Journal of Infectious Diseases</i> , 2018, 218, 1611-1621.	4.0	8
59	Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes. <i>Journal of Virology</i> , 2020, 94, .	3.4	7
60	Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120's gp41 stability. <i>Virology</i> , 2005, 337, 136-148.	2.4	6
61	Performance of human papillomavirus DNA detection in residual specimens taken for Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid amplification testing in men who have sex with men. <i>Sexually Transmitted Infections</i> , 2021, 97, 541-546.	1.9	5
62	Amino acid motifs in both the major and minor capsid proteins of HPV51 impact antigenicity and infectivity. <i>Journal of General Virology</i> , 2015, 96, 1842-1849.	2.9	4
63	Human papillomavirus (HPV) vaccination and oropharyngeal HPV in ethnically diverse, sexually active adolescents: community-based cross-sectional study. <i>Sexually Transmitted Infections</i> , 2021, 97, 458-460.	1.9	2
64	Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England. <i>Vaccine</i> , 2021, 39, 4210-4218.	3.8	2
65	HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London. <i>Sexually Transmitted Infections</i> , 2021, 97, 382-386.	1.9	2
66	Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine. <i>Vaccine</i> , 2022, 40, 1198-1202.	3.8	2
67	Sexually active students' acceptability of providing saline oral samples for future human papillomavirus testing. <i>International Journal of STD and AIDS</i> , 2017, 28, 1464-1465.	1.1	1
68	Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay. <i>MethodsX</i> , 2022, 9, 101776.	1.6	1
69	Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies. <i>Microbiology Spectrum</i> , 2022, , e0077922.	3.0	0